

In the Claims:

No claims have been amended herein. Please cancel claims 13-18 without prejudice to continued prosecution. The claims and their status are shown below.

1. (Original) A method for treating Alzheimer's Disease in a patient in need of such treatment comprising administering an effective amount of a pharmaceutical composition comprising a protein with the amino acid sequence of SEQ ID NO:1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.
2. (Original) A method according to claim 1, wherein the carrier is aqueous.
3. (Original) A method according to claim 1, wherein the composition further comprises an cholinesterase inhibitor.
4. (Original) A method according to claim 3, wherein the cholinesterase inhibitor is selected from the group consisting of ambenonium, adrophonium, methylphysostigmine, neostigmine, pyridostigmine, and pharmaceutically acceptable salts thereof.
5. (Original) A method according to claims 3, wherein the cholinesterase inhibitor is an acetylcholinesterase inhibitor.
6. (Original) A method according to claim 5, wherein the acetylcholinesterase inhibitor is selected from the group consisting of tacrine, galanthamine, and pharmaceutically acceptable salts thereof.
7. (Withdrawn) A pharmaceutical composition suitable for treatment of Alzheimer's disease, comprising a protein with the amino acid sequence of SEQ ID NO:1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefore.
8. (Withdrawn) A composition according to claim 7, wherein the carrier is aqueous.
9. (Withdrawn) A composition according to claim 7, further comprising a cholinesterase inhibitor.
10. (Withdrawn) A composition according to claim 9, wherein the cholinesterase inhibitor is selected from the group consisting of ambenonium, adrophonium, methylphysostigmine, neostigmine, pyridostigmine, and pharmaceutically acceptable salts thereof.
11. (Withdrawn) A composition according to claim 9, wherein the cholinesterase inhibitor is an acetylcholinesterase inhibitor.

Applicant : Girish Kotwal et al.
Serial No. : 09/889,624
Filed : November 7, 2001
Page : 3 of 5

Attorney's Docket No.: 17541-033001

12. (Withdrawn) A composition according to claim 11, wherein the acetylcholinesterase inhibitor is selected from the group consisting of tacrine, galanthamine, and pharmaceutically acceptable salts thereof.

13-18. (Canceled)